Download Files:
Sampatrilat
SKU
HY-123348-1 mg
Category Reference compound
Tags Angiotensin-converting Enzyme (ACE);Neprilysin, Inflammation/Immunology; Cardiovascular Disease, Metabolic Enzyme/Protease
$287 – $3,383
Products Details
Product Description
– Sampatrilat (UK-81252) is a potent and orally active vasopeptidase inhibitor of ACE and neutral endopeptidase (NEP). Sampatrilat inhibits C-domain ACE (Ki=13.8 nM) 12.4-fold more potent than that for the N-domain (Ki=171.9 nM). Sampatrilat (UK-81252) can be used for the study of chronic heart failure and blood pressure regulation[1][2].
Web ID
– HY-123348
Storage Temperature
– -20°C (Powder, sealed storage, away from moisture)
Shipping
– Blue Ice
Applications
– COVID-19-anti-virus
Molecular Formula
– C26H40N4O9S
References
– [1]Sharma RK, et al. The Dynamic Nonprime Binding of Sampatrilat to the C-Domain of Angiotensin-Converting Enzyme. J Chem Inf Model. 2016 Dec 27;56(12):2486-2494.|[2]Maki T, et al. Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation.J Pharmacol Exp Ther. 2003 Apr;305(1):97-105.
CAS Number
– 129981-36-8
Molecular Weight
– 584.68
Compound Purity
– 99.22
SMILES
– OC([C@H](CNC([C@@H](NS(C)(=O)=O)CCCCN)=O)CC1(CCCC1)C(N[C@H](C(O)=O)CC2=CC=C(O)C=C2)=O)=O
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology; Cardiovascular Disease
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– Angiotensin-converting Enzyme (ACE);Neprilysin
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.